Drug Profile
Research programme: heavy metal poisoning therapeutics - Medesis Pharma
Alternative Names: Americium decorporation - Medesis Pharma; Curium decorporation - Medesis Pharma; NU 03Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Medesis Pharma
- Developer CEA; Medesis Pharma
- Class Radioprotectives
- Mechanism of Action Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Heavy metal poisoning
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Heavy-metal-poisoning in France (Inhalation, Spray)
- 31 Mar 2021 Preclinical development is ongoing in France (Inhalation, Spray)
- 28 Aug 2018 No recent reports of development identified for preclinical development in Heavy-metal-poisoning in France (Inhalation, Spray)